JPRN-UMIN000034410招募中未知
A phase 2 study of induction chemotherapy followed by chemoradiotherapy for patients with borderline resectable pancreatic cancer - A phase 2 study of induction chemotherapy followed by chemoradiotherapy for patients with borderline resectable pancreatic cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Contraindication of nab-PTX, GEM, TS-1 2) Pleuritic effusion refractory to diuretics 3) Presence of distant metastasis 4) Presence of concurrent advanced cancer 5) Presence of clinically obvious infection 6) Prior radiotherapy to abdominal lesions 7) Previous history of myocardial infarction within three months 8) Severely mental retardation 9) Current status of pregnancy and lactation, or the possibility of these statuses.
研究者
相似试验
进行中（未招募）
不适用
Phase I/II study on induction chemotherapy followed by chemoradiation with or without lapatinib, a dual EGFR/ErbB2 kinase inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinomaEUCTR2006-002667-33-BEEuropean Organisation for Research and Treatment of Cancer
已完成
2 期
The phase II study of induction chemotherapy with cetuximab/S-1/low dose cisplatin for oral squamous cell carcinoma patientsoral squamous cell carcinomaJPRN-UMIN000014632The workshop of chemotherapy for oral cancer55
未知
2 期
A Phase II study of induction chemotherapy S-1 and CDDP in patients with FDG-PET positive N2 disease of non-small cell lung cancer.JPRN-C000000358Fukushima Medical University25
进行中（未招募）
不适用
Chemotherapy then Radiation then Immediate Curative Surgery for operable rectal cancerRectal adenocarcinomaEUCTR2010-023083-40-GBCardiff University62
进行中（未招募）
不适用
Randomised phase II trial on primary chemotherapy with high-dose Methotrexate and high-dose Cytarabine with or without Thiotepa, and with or without Rituximab, followed by brain irradiation vs high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed Primary CNS Lymphoma. - IELSG 32EUCTR2009-012432-32-GBniversity Hospital Southampton NHS Foundation Trust126